Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: A study of the Eastern Cooperative Oncology Group (ECOG), E5995

Michael S. Gordon, Molly L. Young, Martin S. Tallman, Larry D. Cripe, John M. Bennett, Elisabeth M. Paietta, Walter Longo, Henry Gerad, Joseph Mazza, Jacob M. Rowe

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

2-Chlorodeoxyadenosine (2-CdA) is a purine analog which has anti-leukemic activity in phase II trials in pediatric acute myeloid leukemia (AML) patients. An adult phase I trial suggested possible similar activity although neurotoxicity at higher doses was seen. We conducted a phase II trial of 2-CdA in patients with relapsed or refractory AML. 2-CdA was administered by continuous intravenous infusion at a dose of 17 mg/m2 per day x5 days. Patients not achieving aplasia by day 21 were eligible for a second course of therapy. Fifteen patients (nine relapsed and six refractory AML) were enrolled including seven men and eight women with a median age of 60 years and median ECOG PS of 1. There were five deaths on study due to infections (two), AML (two), or hepatic failure (one). The 2-CdA was well tolerated without severe nausea, vomiting or stomatitis (all <grade 2). No severe neurologic complications related to 2-CdA were seen. Grade 4 myelosuppression occurred in nearly all patients with prolonged periods of pancytopenia and BM hypoplasia seen in most. There were no complete responses, though bone marrow aplasia was achieved in eight patients. 2-CdA as a single agent, in the doses used in this study, is ineffective therapy for relapsed or refractory AML. Copyright (C) 2000 Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)871-875
Number of pages5
JournalLeukemia Research
Volume24
Issue number10
DOIs
StatePublished - Oct 2000
Externally publishedYes

Fingerprint

Cladribine
Acute Myeloid Leukemia
Stomatitis
Pancytopenia
Liver Failure
Intravenous Infusions
Nausea
Nervous System
Vomiting
Bone Marrow
Pediatrics
Therapeutics
Infection

Keywords

  • 2-Chlorodeoxyadenosine
  • Acute myeloid leukemia
  • Chemotherapy
  • Purine analog
  • Salvage therapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia : A study of the Eastern Cooperative Oncology Group (ECOG), E5995. / Gordon, Michael S.; Young, Molly L.; Tallman, Martin S.; Cripe, Larry D.; Bennett, John M.; Paietta, Elisabeth M.; Longo, Walter; Gerad, Henry; Mazza, Joseph; Rowe, Jacob M.

In: Leukemia Research, Vol. 24, No. 10, 10.2000, p. 871-875.

Research output: Contribution to journalArticle

Gordon, Michael S. ; Young, Molly L. ; Tallman, Martin S. ; Cripe, Larry D. ; Bennett, John M. ; Paietta, Elisabeth M. ; Longo, Walter ; Gerad, Henry ; Mazza, Joseph ; Rowe, Jacob M. / Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia : A study of the Eastern Cooperative Oncology Group (ECOG), E5995. In: Leukemia Research. 2000 ; Vol. 24, No. 10. pp. 871-875.
@article{d8e5f8e0195c41f3a9d3d5144ab85f11,
title = "Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: A study of the Eastern Cooperative Oncology Group (ECOG), E5995",
abstract = "2-Chlorodeoxyadenosine (2-CdA) is a purine analog which has anti-leukemic activity in phase II trials in pediatric acute myeloid leukemia (AML) patients. An adult phase I trial suggested possible similar activity although neurotoxicity at higher doses was seen. We conducted a phase II trial of 2-CdA in patients with relapsed or refractory AML. 2-CdA was administered by continuous intravenous infusion at a dose of 17 mg/m2 per day x5 days. Patients not achieving aplasia by day 21 were eligible for a second course of therapy. Fifteen patients (nine relapsed and six refractory AML) were enrolled including seven men and eight women with a median age of 60 years and median ECOG PS of 1. There were five deaths on study due to infections (two), AML (two), or hepatic failure (one). The 2-CdA was well tolerated without severe nausea, vomiting or stomatitis (all",
keywords = "2-Chlorodeoxyadenosine, Acute myeloid leukemia, Chemotherapy, Purine analog, Salvage therapy",
author = "Gordon, {Michael S.} and Young, {Molly L.} and Tallman, {Martin S.} and Cripe, {Larry D.} and Bennett, {John M.} and Paietta, {Elisabeth M.} and Walter Longo and Henry Gerad and Joseph Mazza and Rowe, {Jacob M.}",
year = "2000",
month = "10",
doi = "10.1016/S0145-2126(00)00043-6",
language = "English (US)",
volume = "24",
pages = "871--875",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia

T2 - A study of the Eastern Cooperative Oncology Group (ECOG), E5995

AU - Gordon, Michael S.

AU - Young, Molly L.

AU - Tallman, Martin S.

AU - Cripe, Larry D.

AU - Bennett, John M.

AU - Paietta, Elisabeth M.

AU - Longo, Walter

AU - Gerad, Henry

AU - Mazza, Joseph

AU - Rowe, Jacob M.

PY - 2000/10

Y1 - 2000/10

N2 - 2-Chlorodeoxyadenosine (2-CdA) is a purine analog which has anti-leukemic activity in phase II trials in pediatric acute myeloid leukemia (AML) patients. An adult phase I trial suggested possible similar activity although neurotoxicity at higher doses was seen. We conducted a phase II trial of 2-CdA in patients with relapsed or refractory AML. 2-CdA was administered by continuous intravenous infusion at a dose of 17 mg/m2 per day x5 days. Patients not achieving aplasia by day 21 were eligible for a second course of therapy. Fifteen patients (nine relapsed and six refractory AML) were enrolled including seven men and eight women with a median age of 60 years and median ECOG PS of 1. There were five deaths on study due to infections (two), AML (two), or hepatic failure (one). The 2-CdA was well tolerated without severe nausea, vomiting or stomatitis (all

AB - 2-Chlorodeoxyadenosine (2-CdA) is a purine analog which has anti-leukemic activity in phase II trials in pediatric acute myeloid leukemia (AML) patients. An adult phase I trial suggested possible similar activity although neurotoxicity at higher doses was seen. We conducted a phase II trial of 2-CdA in patients with relapsed or refractory AML. 2-CdA was administered by continuous intravenous infusion at a dose of 17 mg/m2 per day x5 days. Patients not achieving aplasia by day 21 were eligible for a second course of therapy. Fifteen patients (nine relapsed and six refractory AML) were enrolled including seven men and eight women with a median age of 60 years and median ECOG PS of 1. There were five deaths on study due to infections (two), AML (two), or hepatic failure (one). The 2-CdA was well tolerated without severe nausea, vomiting or stomatitis (all

KW - 2-Chlorodeoxyadenosine

KW - Acute myeloid leukemia

KW - Chemotherapy

KW - Purine analog

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=0033843386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033843386&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(00)00043-6

DO - 10.1016/S0145-2126(00)00043-6

M3 - Article

C2 - 10996206

AN - SCOPUS:0033843386

VL - 24

SP - 871

EP - 875

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 10

ER -